Division of Vascular & Endovascular Surgery, Department of Surgery, University of Hong Kong Medical Centre, Hong Kong, China.
Phlebology. 2022 Jul;37(6):425-431. doi: 10.1177/02683555221082358. Epub 2022 Mar 26.
Great saphenous vein diameter (GSV) of >8 mm was predictor of recanalization following Venaseal cyanoacrylate treatment. The aim of this study was to report our modified protocol with a single extra-drop for treatment for GSV>8 mm, and comparative duplex results in closure rates.
Patients in our single-centre registry treated with Venaseal were followed up by serial duplex examinations at week 1 and month(s)- 1, 6, 12, 18, 24, and then annually. The primary endpoint was successful obliteration of the GSV, secondary endpoints were closure distance from Saphenofemoral junction (SFJ), presence of endovenous glue-induced thrombosis (EGIT) or deep vein thrombosis.
A total of 243 legs in 123 consecutive patients with duplex-proven SFJ/GSV incompetence were included in this study between September 2014 and October 2020. The median duplex follow-up period of this cohort of patients was 24 (range 0.2-58) months. Comparing closure rates in GSV diameter ≥8 mm treated with normal protocol, the 'extra-drop protocol' significantly improved closure rates ( = .034). However, the closure rates of ≥8 mm GSV treated with 'extra-drop protocol' was still not as good as GSV <8 mm ( < .001). There were no statistically significant differences in the stump distance between the three groups and no difference in the occurrence of EGIT. There were no deep vein thrombosis.
Our experience showed that VenaSeal cyanoacrylate worked best in GSV<8 mm diameter. Even in GSV diameter of ≥8 mm which has a higher recanalization rate on follow-up duplex, our modified extra-drop protocol significantly improved the closure rates, and did not predispose to development of EGIT.
股浅静脉直径(GSV)>8mm 是 Venaseal 氰基丙烯酸酯治疗后再通的预测指标。本研究旨在报告我们的改良方案,即对 GSV>8mm 的患者单次额外滴注治疗,并比较其在闭合率方面的双功能超声检查结果。
在我们的单中心注册中心,接受 Venaseal 治疗的患者在第 1 周和第 1、6、12、18、24 个月以及随后每年进行系列双功能超声检查。主要终点是 GSV 成功闭塞,次要终点是股隐静脉连接处(SFJ)的闭合距离、静脉内胶诱导血栓形成(EGIT)或深静脉血栓形成的存在。
2014 年 9 月至 2020 年 10 月,共纳入 243 条腿 123 例经双功能超声证实 SFJ/GSV 功能不全的患者,纳入本研究。该患者队列的中位双功能超声随访时间为 24(范围 0.2-58)个月。比较 GSV 直径≥8mm 采用常规方案和“额外一滴”方案治疗的闭合率,“额外一滴”方案显著提高了闭合率(=0.034)。然而,“额外一滴”方案治疗 GSV 直径≥8mm 的闭合率仍不如 GSV<8mm(<0.001)。三组间残端距离无统计学差异,EGIT 发生率无差异。无深静脉血栓形成。
我们的经验表明,VenaSeal 氰基丙烯酸酯在 GSV<8mm 直径时效果最佳。即使在 GSV 直径≥8mm 的患者中,随访双功能超声显示再通率较高,我们的改良“额外一滴”方案也显著提高了闭合率,且不会导致 EGIT 的发生。